Yokogawa Develops N-IO Standard Field Enclosure and Control System Virtualization Platform
Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed an N-IO standard field enclosure and a control system virtualization platform. The enclosure is a weatherproof remote IO cabinet that stores IO devices used by the CENTUM(R) VP integrated production control system and the ProSafe(R)-RS safety instrumented system, and the virtualization platform enables the control of multiple virtual devices on a single server. By reducing the amount of time and effort to engineer a new system, these solutions help to both speed up project execution and reduce total cost of ownership (TCO). The N-IO standard field enclosure is scheduled to be released in February 2018, and the virtualization platform will be released in May 2018.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005010/en/
N-IO Standard Field Enclosure (Photo: Yokogawa Electric Corporation)
As global competition intensifies and the market environment changes, manufacturers want to set up production facilities even more quickly. Yokogawa is responding to this need using the agile project execution concept that improves agility. Agile project execution is an innovative approach to utilizing standardized technology and flexible project execution processes that keep automation off the critical path during project execution. The result is a lower cost of installation and maintenance, and the lowest TCO, while reducing the risks of project execution and delivery.
For improved agility in project execution, Yokogawa developed the N-IO (Network IO) field IO device for CENTUM VP R6.01 (released in November 2014) and ProSafe-RS R4.01.00 (released in October 2015). Equipped with a module that can handle multiple IO signal types, the N-IO device can handle both analog and digital IO signals, which account for the majority of IO signal traffic. With this device, the signal type for each IO point can be configured solely through software settings. This eliminates the need to replace IO modules and wiring when changing sensor types and wiring layouts during engineering, and when changing sensor types during a plant revamp. This significantly reduces workload and speeds up project implementation.
To realize the agile project execution concept Yokogawa has now developed the N-IO standard field enclosure and a control system virtualization platform. The enclosure is a remote IO cabinet that stores the N-IO device, a key component of the CENTUM VP and ProSafe-RS systems, and the virtualization platform enables the operation of multiple virtual machines on a single server. Together with its N-IO and Automation Design Suite (AD suite) integrated engineering environment*, Yokogawa uses virtualization technology to reduce plant construction costs and speed up project implementation. This helps to eliminate the risk of project delays and ensure on-time delivery.
1. N-IO standard field enclosure
Many conventional cabinets for storing IO devices are designed to be installed in air-conditioned instrumentation rooms. For outdoor use, it is necessary to design special dustproof and water resistant cabinets. The N-IO standard field enclosure developed for the CENTUM VP and ProSafe-RS systems is a dustproof and water resistant remote IO cabinet that can be installed outdoors. By allowing the configuration of signal types through software settings, this enclosure eliminates the need for further design modifications. As such, it can be delivered directly to customers without further modification, for faster project implementation.
2. Control system virtualization platform
Multiple PCs for operation, monitoring, and other purposes are typically used when configuring a control system, and the cost of procuring and maintaining these computers is substantial. Yokogawa’s control system virtualization platform enables a single server to perform the work of multiple virtual PCs, thus reducing the number of PCs required to configure a control system. With this platform, both the hardware and software required to build a virtual environment are provided. By means of this virtualized server environment, it is possible to separately update and make modifications to hardware and software as required.
In preparation for system installation, Yokogawa carries out the engineering and conducts the factory acceptance test (FAT) of the software on a machine different from the one that will be actually used. Yokogawa delivers the hardware directly to the customer, and then installs the completed software. This speeds up implementation and prevents project delays.
Major Target Markets
Oil and gas, petrochemicals, chemicals, electric power, pulp and paper, pharmaceuticals, food, iron and steel, water supply and wastewater treatment, non-ferrous metals, metal, cement, etc.
Operation monitoring and automatic control of plants
For more information
About the CENTUM series
Yokogawa released its CENTUM distributed control system (DCS) in 1975, a world first. CENTUM VP is the ninth generation in the CENTUM series. Known for their rugged performance, CENTUM systems set high standards for engineering and technology excellence while ensuring backwards compatibility with previous system versions and support of the latest technology applications. Knowledge-driven engineering lies at the heart of CENTUM, a Yokogawa flagship product that has been proudly serving the process industry, over the past 40+ years.
Released in February 2005, the ProSafe-RS safety instrumented system helps prevent accidents by detecting abnormal conditions in plant operations and initiating emergency actions such as a plant shutdown. An independent certification body has certified that ProSafe-RS conforms to the IEC61508 international safety standard and can be used in SIL3 applications. Unlike conventional safety instrumented systems and distributed control systems, which are regarded as having different roles and functions and operate separately, the operation of ProSafe-RS and the CENTUM integrated control system can be fully integrated.
Yokogawa's global network of 113 companies spans 60 countries. Founded in 1915, the US$3.5 billion company engages in cutting-edge research and innovation. Yokogawa is active in the industrial automation and control (IA), test and measurement, and aviation and other businesses segments. The IA segment plays a vital role in a wide range of industries including oil, chemicals, natural gas, power, iron and steel, pulp and paper, pharmaceuticals, and food. Targeting this segment, Yokogawa helps companies maximize their profits by offering a wide range of highly reliable products and working with the subsidiary KBC Advanced Technologies to provide premium solutions and services. For more information about Yokogawa, please visit www.yokogawa.com
* An engineering environment that Yokogawa has developed by leveraging engineering know-how accumulated in many projects. AD suite modularizes control applications and enables them to be used in similar facilities, increasing the efficiency of engineering and ensuring consistent quality.
The names of companies, products, and brands in this text are registered trademarks or trademarks of the respective holders.
Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30 | Pressemelding
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr